XING IMAGING is a CRO service provider of nuclear drug transformation and clinical trial imaging, focusing on the field of medical and health services, providing pilot test transformation of new PET drugs, production and preparation of new PET drugs with diagnostic companion diagnostics for clinical trials, and PET/CT image scanning services for new PET drugs , PET image reading management services and other services. Recently, a subsidiary of Dongcheng Pharmaceutical intends to acquire 100% of the shares of XING IMAGING for US$30.2 million.
This article is transferred from: https://www.itjuzi.com/merger/9535
This site is only for collection, and the copyright belongs to the original author.